Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Stopped Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

Conditions

• HER2 Expressing Solid Tumours

Interventions

• DRUG: CD3/HER2 bispecific monoclonal antibody

Sponsor

Ichnos Sciences SA

Collaborators

• [object Object]